Results 191 to 200 of about 493,465 (339)

Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists

, 2016
Fernando B. de Moura, Lance Richard McMahon   +1 more
openalex   +1 more source

Amyloid Beta in Alzheimer's Disease: Mechanisms, Biomarker Potential, and Therapeutic Targets

CNS Neuroscience &Therapeutics, Volume 31, Issue 12, December 2025.
The limited clinical efficacy of anti‐Aβ antibodies has challenged the Aβ hypothesis, compelling the integration of key mechanisms—including neuroinflammation, mitochondrial dysfunction, oxidative stress, and post‐translational modifications of Aβ—into a revised model of Alzheimer's disease.
Shamseddin Ahmadi, Shiler Khaledi, Kimia Ahmadi, Kambiz Hassanzadeh   +3 more
wiley   +1 more source

Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. [PDF]

Psychopharmacology (Berl), 2018
Maggio SE, Saunders MA, Baxter TA, Nixon K, Prendergast MA, Zheng G, Crooks P, Dwoskin LP, Slack RD, Newman AH, Bell RL, Bardo MT.   +11 more
europepmc   +1 more source

Relationships of agonist properties to the single channel kinetics of nicotinic acetylcholine receptors

, 1988
Roger L. Papke, Glenn L. Millhauser, Zoe R. Lieberman, Robert E. Oswald   +3 more
openalex   +1 more source

The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 does not affect food intake in rats [PDF]

, 2022
Adrianne M. DiBrog, Katherine A. Kern, Ashmita Mukherjee, Johnathan T. Przybysz, Elizabeth G. Mietlicki‐Baase   +4 more
openalex   +1 more source

Engineering exosomes for Alzheimer's disease: Multi‐target therapeutic strategies from pathogenesis to clinical translation

Clinical and Translational Medicine, Volume 15, Issue 12, December 2025.
Exosomes, modified through multidimensional approaches including physical, chemical and genetic means, and equipped with brain‐targeted peptides and therapeutic agents, are capable of crossing the blood‒brain barrier for precise delivery. They can simultaneously remove amyloid‐beta plaques and neurofibrillary tangle, inhibit neuroinflammation, and pave
Yuehan Zhang, Zhenyang Li, Haien Guan, Zhenhua Qiu, Chunlin Zou   +4 more
wiley   +1 more source

Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients

Drug, Healthcare and Patient Safety, 2010
Zheng-Xiong XiNational Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USAAbstract: Smoking is still the most prominent cause of preventable premature death in the United States and an increasing cause of morbidity and mortality ...
Zheng-Xiong Xi
doaj  

Nicotinic agonist binding site mapped by methionine- and tyrosine-scanning coupled with azidochloropyridinyl photoaffinity labeling.

Journal of Medicinal Chemistry, 2009
M. Tomizawa, T. Talley, John F. Park, D. Maltby, K. Medzihradszky, K. A. Durkin, J. Cornejo-Bravo, A. Burlingame, J. Casida, P. Taylor   +9 more
semanticscholar   +1 more source

Risk Factors for Cardiovascular and Metabolic Disease: Integrating Traditional and Novel Paradigms

iNew Medicine, Volume 1, Issue 1, December 2025.
ABSTRACT Cardiovascular and metabolic diseases (CVMD), encompassing atherosclerotic cardiovascular disease (ASCVD), heart failure, obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD), remain the leading global cause of morbidity and mortality.
Zhihua Wang, Shuo Chen, Suowen Xu, Jianping Weng   +3 more
wiley   +1 more source

Chemical-Scale Studies on the Role of a Conserved Aspartate in Preorganizing the Agonist Binding Site of the Nicotinic Acetylcholine Receptor

, 2006
Amanda L. Cashin, Michael M. Torrice, Kathryn A. McMenimen, Henry A. Lester, Dennis A. Dougherty   +4 more
openalex   +2 more sources